+1-206-701-6702
+44-020-8133-4027
+050-5539-1737
+91-848-285-0837
Press Release: Metabolism Drugs Market to Surpass US$ 9.9 Billion Threshold by 2026 Globally
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Metabolism Drugs Market – Insights
Metabolism diseases results from malfunctioning or inadequate function of the body’s original metabolism. Metabolism diseases can also have a genetic origin, as they can be caused by genetic birth defects as well. Metabolic diseases from genetic defects have low incidence and prevalence rate. Metabolism involves breaking down of carbohydrates, proteins, and fats present in the consumed food, to generate energy.
Furthermore, metabolism also involves excretion of nitrogen through urine, and breaking down or converting other substances and chemicals. This metabolism is carried out by certain enzymes and proteins designated for the respective role. However, metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are mean to.
Metabolic disorders occur due to buildup of proteins, lipids, glycogen, urea, calcium stones, and toxic substances among others. Each of these molecules have certain designated metabolic pathways, and metabolic agents (enzymes, proteins) at work. Inability of these agents to carry out their tasks cause buildup of the molecules in the blood and other places. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease.
Rising prevalence of metabolic diseases is expected to support growth of the metabolism drugs market over the forecast period
Metabolic diseases is a wide category and there are several metabolism disorders caused due to clinically simple defects as well difficult to treat genetic disorders. For instance, obesity is most common type of metabolic disorder and is closely related to metabolic syndrome (a cluster of clinical conditions such as high blood sugar and triglycerides). According to the World Health Organization (WHO), over 650 million people aged 18 years and above were obese in 2016.
Another condition called lysosomal storage disease is a rare disorder, however, a significant number of people are affected with this disease. According to study published in Molecular Genetics and Metabolism Reports in December 2017, lysosomal storage disease has incidence rate of 1 in 4000 to 1 in 13,000 live births. Lysosomal storage disease consists of 60 genetic abnormalities with problematic enzyme function.
Moreover, other rare diseases such as Hunter syndrome (Mucopolysaccaridosis type II (MPS II)), though rare, are life-threatening diseases with no curative treatment available, thus patients are made to rely on available therapies. According to the National Institute of Health 2018 report, Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Increasing incidence of hunter syndrome is expected to boost the metabolism disease drugs market. For instance, in 2014, around 970 patients were enrolled in Hunter Outcome Survey (HOC), which increased to 1195 patients in 2017.
The global metabolism drugs market size was valued at US$ 5,765.3 million in 2017, and is expected to witness a robust CAGR of 6.3% over the forecast period (2018 – 2026).
Figure 1. Global Metabolism Drugs Market Share US$ Mn, by Region, 2018
Source: Coherent Market Insights Analysis (2018)
Newer therapy launches are expected to boost growth of the metabolism drugs market over the forecast period
Manufacturers try to find potential revenue gaining opportunities in each and every disease segment by offering effective therapies. Though the prevalence of rare diseases is low, patients rely on therapies that are made available irrespective of their price. These drugs are difficult to develop, and in turn expensive, still manufacturers create therapies for chronic and difficult-to-cure rare diseases, selling them at higher prices.
Approvals to innovative therapies such as enzyme replacement therapy are expected to influence manufacturers to develop novel therapies in the market. This in turn, is expected to support the metabolism drugs market growth over the forecast period. The U.S. Food and Drug Administration (FDA) approved multiple drugs for gaucher disease. For instance, in 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by FDA for type 1 gaucher disease.
Moreover, research and development of novel therapies for treatment of rare metabolism diseases such as pompe, and others is expected to positively impact the metabolism drugs market growth. For instance, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of Pompe disease. Moreover, novel gene and RNAi therapies are also under research for treatment of these diseases.
Figure 2. Global Metabolism Drugs Market Share (%), by Application, 2018
Source: Coherent Market Insights Analysis (2018)
However, high cost associated with the treatment and long duration of the treatments is expected to restrain growth of the metabolism drugs market. For instance, according to a research paper published by Harvard School, in 2016, Lumizyme accounted for US$ 100,000 per year for children and US$ 300,000 per year for adult treatments for pompe disease.
Some of the major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Increasing prevalence of pompe disease is expected to create lucrative opportunities for pharmaceutical manufacturers to develop and commercialize novel treatments for the disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated incidence of Pompe disease in Holland is 1 in 40,000, in Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and in Caucasian is 1 in 100,000 population. Initiatives from government organizations for drug research and development is supporting growth of the metabolism drugs market.
For instance, in 2016, the scientist from National Institutes of Health researchers collaborated with National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) and researchers identified a new molecule that shows promising approach for treatment of the rare gaucher disease. Moreover, in 2014, European Gaucher Alliance launched Gaucher Awareness Day to spread awareness about this rare disease among the population in Europe.
Market Dynamics
Robust pipeline with various therapies such as enzyme replacement therapy, gene therapy, and small molecule drugs is expected to boost the metabolism drugs market over the forecast period. Increased understanding of diseases and rising number of diagnosed patients are expected to increase the number of patients undergoing treatment.
High prevalence of metabolic diseases is expected to support the growth of the metabolism drugs market. For instance, according to the National Institute of Health (NIH) 2018 report, frequency of hunter syndrome is 1 in 100,000 to 1 in 160,000 in males. Enzyme replacement therapy is expected to show significant growth in the metabolism drugs market over the forecast period.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 34 market data tables and 43 figures on "Metabolism Drugs Market - Global forecast to 2026”.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
